Creekmur Asset Management LLC Acquires 4,218 Shares of Solventum Corporation $SOLV

Creekmur Asset Management LLC raised its holdings in shares of Solventum Corporation (NYSE:SOLV) by 39.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,803 shares of the company’s stock after acquiring an additional 4,218 shares during the period. Creekmur Asset Management LLC’s holdings in Solventum were worth $1,123,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Solventum by 0.7% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock worth $1,500,000 after purchasing an additional 140 shares during the period. Tradition Wealth Management LLC raised its position in Solventum by 1.6% in the 1st quarter. Tradition Wealth Management LLC now owns 8,830 shares of the company’s stock worth $671,000 after purchasing an additional 143 shares during the period. Applied Finance Capital Management LLC raised its position in Solventum by 3.8% in the 2nd quarter. Applied Finance Capital Management LLC now owns 4,428 shares of the company’s stock worth $336,000 after purchasing an additional 162 shares during the period. SouthState Corp raised its position in Solventum by 31.9% in the 1st quarter. SouthState Corp now owns 699 shares of the company’s stock worth $53,000 after purchasing an additional 169 shares during the period. Finally, HB Wealth Management LLC raised its position in Solventum by 5.6% in the 2nd quarter. HB Wealth Management LLC now owns 3,463 shares of the company’s stock worth $263,000 after purchasing an additional 185 shares during the period.

Solventum Price Performance

Shares of Solventum stock opened at $69.24 on Friday. The company’s fifty day simple moving average is $72.50 and its two-hundred day simple moving average is $72.28. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92. The firm has a market cap of $12.00 billion, a PE ratio of 32.05, a price-to-earnings-growth ratio of 2.83 and a beta of 0.50. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. During the same quarter last year, the firm posted $1.56 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, equities analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SOLV. UBS Group began coverage on shares of Solventum in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and issued a $94.00 target price (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Wells Fargo & Company lifted their target price on shares of Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Monday, September 15th. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. Finally, Jefferies Financial Group started coverage on shares of Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.